Trial Profile
The ACUITY trial: a randomized comparison of Angiomax (Bivalirudin) versus heparin (unfractionated heparin or enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Bivalirudin (Primary) ; Abciximab; Enoxaparin sodium; Enoxaparin sodium; Eptifibatide; Heparin; Tirofiban
- Indications Acute coronary syndromes
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ACUITY
- Sponsors The Medicines Company
- 25 Sep 2023 Results of Individual Patient Data Meta-Analysis , from MATRIX, VALIDATE-SWEDEHEART, ISAR-REACT 4, ACUITY and BRIGHT; comparing the outcomes of bivalirudin and heparin in patients with non-ST-segment-elevation myocardial infarction undergoing PCI, published in the Circulation
- 20 Apr 2016 Results of a pooled analysis from REPLACE-2, ACUITY and HORIZONS-AMI Trials (n=3641) published in the American Journal of Cardiology
- 01 Dec 2015 Results(n=14,784) of pooled analysis of this and other two trials (see profile 21574 and 266431) published in the American Journal of Cardiology